| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | DOG1; TAOS2; ORAOV2; TMEM16A |
| Entrez GeneID | 55107; |
| WB Predicted band size | 114kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthetic peptide corresponding to a region derived from internal residues of human anoctamin 1, calcium activated chloride channel |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于ANO1抗体的3篇参考文献示例(内容基于公开研究整理，非真实引用)：
---
1. **文献名称**: "ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeted therapy in head and neck cancer"
**作者**: Huang F, et al.
**摘要**: 研究证实ANO1在头颈部鳞状细胞癌中过表达，并作为EGFR信号通路的关键调节因子。通过特异性ANO1抗体进行免疫组化分析，发现其表达水平与患者对EGFR抑制剂的治疗反应相关，提示其作为生物标志物的潜力。
2. **文献名称**: "TMEM16A confers receptor-activated calcium-dependent chloride conductance and regulates nociception"
**作者**: Seo Y, et al.
**摘要**: 利用ANO1特异性抗体进行免疫荧光染色，发现其在背根神经节的伤害性神经元中高表达。研究揭示ANO1通过介导钙依赖性氯离子流参与疼痛信号传导，为开发镇痛药物提供新靶点。
3. **文献名称**: "Characterization of a novel monoclonal antibody against the N-terminal domain of ANO1 for functional studies"
**作者**: Caputo A, et al.
**摘要**: 报道一种针对ANO1蛋白N端表位的高特异性单克隆抗体的开发与验证。该抗体成功应用于Western blot、免疫沉淀及免疫细胞化学，显著提升了对ANO1亚细胞定位和分子互作的研究精度。
---
注：以上为模拟文献，实际引用请通过PubMed/Google Scholar检索关键词(如"ANO1 antibody"、"TMEM16A biomarker")获取真实论文。
ANO1 (Anoctamin 1), also known as TMEM16A, is a calcium-activated chloride channel protein involved in various physiological processes, including muscle contraction, neuronal excitability, and secretory functions. Antibodies targeting ANO1 are critical tools for studying its expression, localization, and functional roles in both normal and pathological conditions. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to detect ANO1 in tissues and cell lines.
Research has linked ANO1 overexpression to several cancers, such as head and neck squamous cell carcinoma, breast cancer, and gastrointestinal stromal tumors, making its antibodies valuable for cancer biomarker studies. ANO1 is also implicated in smooth muscle disorders (e.g., hypertension, asthma) and neurological conditions, driving interest in its therapeutic targeting. However, challenges remain in ensuring antibody specificity due to homology with other Anoctamin family members (e.g., ANO2. ANO6). Validation methods like knockout models or siRNA knockdown are essential to confirm antibody reliability. Both monoclonal and polyclonal ANO1 antibodies are available, each with distinct advantages depending on the application. Ongoing research continues to refine these tools, aiming to enhance diagnostic accuracy and support drug development targeting ANO1-related pathways.
×
